Ondine Biomedical, Inc. ( (GB:OBI) ) has issued an update.
Ondine Biomedical Inc. announced that Nicolas Loebel, the company’s President and CTO, has increased his shareholding by purchasing 25,000 common shares at 12.6 pence each, bringing his total to 3,538,991 shares. This move signifies confidence in the company’s future, potentially influencing stakeholders and reflecting positively on Ondine’s market positioning as it continues to develop its pioneering photodisinfection treatments.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on this technology, with its nasal photodisinfection system receiving regulatory approvals in Europe, Canada, and other countries under Steriwave®. It is also undergoing FDA clinical trials in the US for further approval.
YTD Price Performance: 40.0%
Average Trading Volume: 514,934
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £49.49M
See more data about OBI stock on TipRanks’ Stock Analysis page.